This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05687266
Recruitment Status : Recruiting
First Posted : January 18, 2023
Last Update Posted : February 6, 2024
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 22, 2027
Estimated Study Completion Date : February 22, 2027